Cefuroxime 750 mg Powder for Injection/Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

cefuroxime 750 mg powder for injection/infusion

flynn pharma limited - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Cefuroxime 250 mg Powder for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

cefuroxime 250 mg powder for solution for injection

stravencon ltd - cefuroxime sodium - powder for solution for injection - 250 milligram(s) - second-generation cephalosporins; cefuroxime

Cefuroxime 750 mg Powder for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

cefuroxime 750 mg powder for solution for injection

stravencon ltd - cefuroxime sodium - powder for solution for injection - 750 milligram(s) - second-generation cephalosporins; cefuroxime

Cefuroxime 1500 mg Powder for solution for injection or infusion Ireland - English - HPRA (Health Products Regulatory Authority)

cefuroxime 1500 mg powder for solution for injection or infusion

stravencon ltd - cefuroxime sodium - powder for solution for injection/infusion - 1500 milligram(s) - second-generation cephalosporins; cefuroxime

Cefuroxime for Injection New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime for injection

viatris limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime  

Cefuroxime 1.5 g powder for solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

cefuroxime 1.5 g powder for solution for injection/infusion

fresenius kabi deutschland gmbh - cefuroxime sodium - powder for solution for injection/infusion - 1.5 gram(s) - second-generation cephalosporins; cefuroxime

CEFUROXIME ANS cefuroxime (as sodium) 1500 mg powder for  injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cefuroxime ans cefuroxime (as sodium) 1500 mg powder for injection vial

southern xp ip pty ltd - cefuroxime sodium, quantity: 1577.7 mg (equivalent: cefuroxime, qty 1500 mg) - injection, powder for - excipient ingredients: - cefuroxime ans is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime ans is not indicated in children less than 40 kg in weight.

CEFUROXIME ANS cefuroxime (as sodium) 750 mg powder for  injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cefuroxime ans cefuroxime (as sodium) 750 mg powder for injection vial

southern xp ip pty ltd - cefuroxime sodium, quantity: 788.9 mg (equivalent: cefuroxime, qty 750 mg) - injection, powder for - excipient ingredients: - cefuroxime ans is indicated in adults and children of 40 kg or greater in weight for the prevention of infections associated with certain surgical procedures of the gastrointestinal (including oesophageal), orthopaedic, cardiovascular and gynaecological systems (including caesarean section) (see section 4.4: special warnings and precautions for use and section 5.2: pharmacokinetic properties).,in the prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents such as metronidazole.,consideration should be given to official guidance on the appropriate use of antibacterial agents, as antibiotic prophylaxis is not required in all gastrointestinal, orthopaedic, cardiovascular and gynaecological procedures or surgeries.,for patients with specific cardiac conditions which predispose them to endocarditis who are undergoing abdominal surgery for which surgical antibiotic prophylaxis is indicated, the prophylaxis regimen should additionally include an antibiotic active against enterococci.,for patients undergoing orthopedic or cardiovascular surgery known to be, or at risk of being, colonised or infected with methicillin-resistant s. aureus (mrsa), add an antibiotic with activity against mrsa, such as vancomycin.,cefuroxime ans is not indicated in children less than 40 kg in weight.

Cefuroxime Multichem New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime multichem

multichem nz limited - cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.6 g equivalent to cefuroxime 1.5 g   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1). indications include - respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septi